Compare ATOS & ICG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOS | ICG |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.8M | 97.1M |
| IPO Year | 2012 | 2023 |
| Metric | ATOS | ICG |
|---|---|---|
| Price | $0.63 | $1.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $6.33 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 1.4M | 114.2K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.43 |
| EPS | N/A | ★ 0.21 |
| Revenue | N/A | ★ $36,367,850.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.98 |
| P/E Ratio | ★ N/A | $8.77 |
| Revenue Growth | N/A | ★ 6.53 |
| 52 Week Low | $0.55 | $0.93 |
| 52 Week High | $1.29 | $7.95 |
| Indicator | ATOS | ICG |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 53.55 |
| Support Level | $0.55 | $1.76 |
| Resistance Level | $0.75 | $2.10 |
| Average True Range (ATR) | 0.05 | 0.17 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 21.90 | 50.00 |
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.